NEW YORK (360Dx) — Svar Life Science, formerly Euro Diagnostica, has signed a strategic agreement to transfer its radioimmunoassay (RIA) portfolio and its Neolisa chromogranin A (CgA) ELISA assay to Diasource ImmunoAssays, the companies announced today.
Under the terms of the deal, Diasource will assume sales of the RIA products beginning Sept. 1 and take over the products' production during the remainder of the year. Diasource will begin selling the Neolisa CgA assay in January 2019, with production transfer following later that year.
Products covered under the arrangement include RIAs for the quantification of a number of peptide hormones involved in critical physiological processes, Diasource said, adding that the Neolisa CgA assay complements its own CgA products.
Additional terms were not disclosed.
"This acquisition is another step in our strategy to position Diasource as a consolidator of manual specialty assays," Diasource CEO Jef Vangenechten said in a statement. "This is our fifth acquisition in the RIA space, and shows once again that we are committed to the long term future servicing and supporting of our considerable RIA customer base worldwide."
Earlier this month, Diasource signed an agreement to take over the RIA portfolio of ZenTech.